Testing a rocking bed during sleep for people with Parkinson's disease
Tests whether a rocking bed used overnight is acceptable for adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Acceptability of the Somnomat Casa for the Treatment of Parkinson's Disease
Key facts
- Where
- Bern and Zurich, SwitzerlandSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT06386497, who can take part
Where in Switzerland
- Insel Gruppe AG University Hospital BernBern, SwitzerlandTaking people
- ETH Zurich, Sensory-Motor Systems Lab, IRISZurich, SwitzerlandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Insel Gruppe AG, University Hospital Bern
- Trial code
- NCT06386497
- Record updated
- 22 May 2026
- Original description
This pilot study aims to evaluate the feasibility and acceptability of nocturnal translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two months in patients with Parkinson's Disease.Read full original descriptionShow less
Overnight Treatment of Parkinson's Disease Using Vestibular Stimulation From a Rocking Bed (Somnomat Casa) - A Feasibility Study
This pilot study aims to evaluate the feasibility and acceptability of nocturnal translational vestibular stimulations (VS) applied by a rocking bed (Somnomat Casa) for two months in patients with Parkinson's Disease.
Inclusion: Informed Consent signed by the subject; PD according to the MDS clinical diagnostic criteria for Parkinson's disease; Suffering from reduced sleep quality as defined by pathological cut-off (score of > 5) on the Pittsburgh Sleep Quality Index (PSQI); Patients with stable antiparkinsonian, antidepressant, and sleep medications for six weeks before intervention and maintained on stable medication during the intervention period; Treatment without bilateral deep brain stimulation; Fluent in German.
Exclusion: Brain disease other than Parkinson's disease (e.g. atypical Parkinsonism, Alzheimer's disease, vascular dementia, multiple sclerosis, stroke, traumatic brain injury, epilepsy, etc.); Dementia as defined by a MOCA score lower than 24/30; Presence of major ongoing psychiatric illness such as acute non-controlled psychosis; Poor general health (e.g. non-controlled diabetes, uncontrolled arterial hypertension, therapy for malignancy); Inability to follow the procedures of the study, e.g. filling out patient questionnaires due to language problems, psychological disorders, dementia, etc. of the participant; Weight > 150kg; Depression with acute suicidal ideation; Participation in another interventional trial within the 30 days preceding and during the present study; Participants with PSQI score lower or equal 5.